Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN) — Form 144: Proposed sale of shares
About this filing
Enliven Therapeutics, Inc. (ELVN) filed Form 144 (proposed sale of shares) with the SEC on Oct 19, 2026. Form 144 is notice that an insider or affiliate plans to sell shares.
Key facts
- Seller
- Collins Helen Louise
- Relationship
- Director
- Shares to sell
- 15,000
- Market value
- $559,800.00
- Approximate sale date
- Oct 19, 2026
- Broker
- Jefferies LLC
- Acquired
- Aug 9, 2022 · Stock Options
Rule 10b5-1 plan · adopted Oct 19, 2025
Remarks
- All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 10/19/2025, and all representations regarding material non-public information were made as of the adoption of the plan.
More ELVN filings
- 10-Q
Filed Nov 5, 2026
- 8-K
Filed Nov 5, 2026
- 4
Filed Nov 3, 2026
- SC 13G/A
Filed Oct 27, 2026
- 4
Filed Oct 21, 2026
- 4
Filed Oct 21, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.